These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11970753)

  • 1. Comparison of in vitro exemestane activity versus other antiaromatase agents.
    Soudon J
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S68-73. PubMed ID: 11970753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
    Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
    Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
    Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of aromatase inhibitors in breast carcinoma.
    Santen RJ; Harvey HA
    Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A summary of second-line randomized studies of aromatase inhibitors.
    Buzdar AU
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):109-14. PubMed ID: 11850214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
    de Jong PC; Blijham GH
    Neth J Med; 1999 Aug; 55(2):50-8. PubMed ID: 10474272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
    Michaud LB; Buzdar AU
    Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
    Goss PE; Hadji P; Subar M; Abreu P; Thomsen T; Banke-Bochita J
    Breast Cancer Res; 2007; 9(4):R52. PubMed ID: 17692126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
    Long BJ; Tilghman SL; Yue W; Thiantanawat A; Grigoryev DN; Brodie AM
    J Steroid Biochem Mol Biol; 1998 Nov; 67(4):293-304. PubMed ID: 9883986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local endocrine effects of aromatase inhibitors within the breast.
    Miller WR; Dixon JM
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):93-102. PubMed ID: 11850212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are differences in the available aromatase inhibitors and inactivators significant?
    Johnson PE; Buzdar A
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4360s-4368s; discussion 4411s-4412s. PubMed ID: 11916226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
    Kijima I; Itoh T; Chen S
    J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
    Murray R
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
    Dixon JM
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):267-75. PubMed ID: 12113050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase inhibitors for breast cancer in postmenopausal women.
    Campos SM
    Oncologist; 2004; 9(2):126-36. PubMed ID: 15047917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
    Carlini P; Michelotti A; Ferretti G; Ricci S; Giannarelli D; Pellegrini M; Cresti N; Di Cosimo S; Bria E; Papaldo P; Fabi A; Ruggeri EM; Milella M; Alimonti A; Salesi N; Cognetti F
    Cancer Invest; 2007 Mar; 25(2):102-5. PubMed ID: 17453821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-aromatase agents in the treatment and prevention of breast cancer.
    Goss P
    Cancer Control; 2002; 9(2 Suppl):2-8. PubMed ID: 11965225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroidal aromatase inhibitors in elderly patients.
    Bajetta E; Zilembo N; Bichisao E; Pozzi P; Toffolatti L
    Crit Rev Oncol Hematol; 2000 Feb; 33(2):137-42. PubMed ID: 10737375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.
    McCloskey EV; Hannon RA; Lakner G; Fraser WD; Clack G; Miyamoto A; Finkelman RD; Eastell R
    Eur J Cancer; 2007 Nov; 43(17):2523-31. PubMed ID: 18029171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
    Buzdar AU
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):468S-72S. PubMed ID: 12538502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.